SynthesisBMC cancer2019
Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review.
Synthesis in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 91 citations in OpenAlex.
- Squamous cell carcinoma arising from ovarian mature cystic teratoma with concurrent cervical high-risk HPV infection and low-grade squamous intraepithelial lesion: a case report.BMC women's health · 2026Article
- Squamous Cell Carcinoma Arising in a Mature Cystic Teratoma of the Ovary Presenting With a Ruptured Sister Mary Joseph Nodule: A Rare Case Report From Northern Tanzania.Clinical case reports · 2026Article
- An Updated Case Report of a Long-Term Survivor With Stage IVB Ovarian Squamous Cell Carcinoma Arising From Mature Cystic Teratoma.The journal of obstetrics and gynaecology research · 2026Article
- Squamous cell carcinoma arising within a mature cystic teratoma of the ovary in a postmenopausal woman: A case report and literature review.Case reports in women's health · 2026Article
- In-Tumor CRISPR-Cas9 Knockout Screening and Novel Therapy Development for Malignant Transformation of Ovarian Teratoma.Cancer science · 2026Article
- Squamous cell carcinoma arising in mature ovarian teratoma: a rare clinical entity.Oxford medical case reports · 2026Article
- Prognostic factors for malignant tumors arising from mature cystic teratomas: a study involving the Kansai Clinical Oncology Group (KCOG-G1305s study).Archives of gynecology and obstetrics · 2025Article
- Article
- High-grade gliomas derived from an ovarian mature teratoma: clonal dynamics and genetic insights.International cancer conference journal · 2025Article
- Mucinous Carcinoma, Mucinous Borderline Tumor and Pseudomyxoma Ovarii in a Cystic Teratoma: A Histological Conundrum.Diagnostics (Basel, Switzerland) · 2025Article
- When Teratomas Turn Brutal: From Indolent to Invasive in Stage IIIB Ovarian Squamous Cell Carcinoma.Cureus · 2025Article
- Ovarian squamous cell carcinoma: clinicopathological features, prognosis and immunotherapy outcomes.Journal of gynecologic oncology · 2025Article
- Squamous cell carcinoma arising from mature cystic teratoma of the ovary in a premenopausal women: A rare case report.International journal of surgery case reports · 2025Article
- Immunotherapy in young adults with mature cystic ovarian Teratoma-Derived squamous cell carcinoma: a case series.Journal of ovarian research · 2025Article
- A rare case of malignant transformation: squamous cell carcinoma arising on the basis of an ovarian mature cystic teratoma.BMC women's health · 2025Article
- Single-Nucleus RNA Sequencing and Spatial Transcriptomics for Squamous Cell Carcinoma Arising From Ovarian Mature Teratoma.Cancer science · 2025Article
- Molecular characterization of ovarian squamous cell carcinoma originating from mature teratoma.Journal of molecular medicine (Berlin, Germany) · 2025Article
- An Adult Massive Retroperitoneal Mature Teratoma: A Case Report and Literature Review.International journal of women's health · 2025Article
- Article
- Mucinous cystadenoma and carcinoid tumor arising from an ovarian mature cystic teratoma in a 60 year-old patient: a case report.Journal of medical case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
background0.17-2% of mature cystic teratoma of the ovary (MCTO) undergo malignant transformation, of which 80% are squamous cell carcinoma (SCC) transformation in MCTO. We aim to investigate the clinical characteristics and treatment of SCC transformation in MCTO
methodsWe systematically searched PubMed database and individual patient data about SCC transformation in MCTO were extracted. The published cases were combined with 6 cases of SCC transformation in MCTO from Qilu Hospital, Shandong University.
resultsThe incidence of SCC transformation in MCTO was 0.3%. A total of 435 cases of SCC transformation in MCTO were enrolled in the analysis. The mean age of diagnosis was 53.5 (range 19-87) years old. The most common clinical manifestations were abdominal pain (47.3%) and abdominal mass (26.0%). StageI,II, III and IV accounted for 50.0, 18.8, 26.8 and 4.4% of all cases, respectively. Patients with stage I had significantly better prognosis than stage II, III and IV patients (P < 0.01). Hysterectomy can improve overall survival (P < 0.01). For patients younger than 45 years old with stageIA orIC, there was no difference in mortality between fertility-sparing and radical surgery (P = 1.00). Adjuvant chemotherapy can improve survival in patients with advanced stage (P = 0.02), and chemotherapy with platinum was related to better prognosis (P = 0.02).
conclusionSCC transformation in MCTO is a rare malignancy mainly occurs in older age. FIGO stage is an independent prognostic factor. Hysterectomy and platinum-based chemotherapy are associated with better survival. Fertility-sparing surgery is feasible for young patients with early stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.